CCRN
CROSS COUNTRY HEALTHCARE INC
$13.18
-0.08%
$426.1M
No data for this timeframe.
Vol
Market Cap$426.1M
Cap SizeSmall Cap
Analyst ConsensusSell (0%)
Inst. Holders8 funds
Inst. Value$34.0M
Inst. Activity5 buys / 0 sells
Insider Activity0B / 1S
Insider Net $-$60.1K
SEC Reports7
Recent Activity
Jun 5, 2026
SEC
Cross Country Healthcare (CCRN) filed a preliminary proxy statement (PREM14A) seeking shareholder approval for its acqui
PREM14A — Impact 7/10
May 7, 2026
SEC
Cross Country Healthcare (CCRN) entered into a definitive agreement to be acquired by Knox Lane in an all-cash transacti
DEFA14A — Impact 8/10
May 7, 2026
SEC
Cross Country Healthcare has entered into a definitive agreement to be acquired by private equity firm Knox Lane in an a
DEFA14A — Impact 8/10
Mar 31, 2026
Insider
Hawkins Amiee Lin sold 583 shares
Chief Operating Officer @ $9.40 ($5.5K)
Mar 31, 2026
Insider
Hawkins Amiee Lin sold 15,958 shares
Chief Operating Officer @ $0.00 ($0.00)
Mar 31, 2026
Insider
Krug Marc S. sold 21,024 shares
Group President, Delivery @ $0.00 ($0.00)
Inst.
CHARLES SCHWAB INVESTMENT MANAGEMENT — ADD
969,458 shares ($7.9M)
Inst.
FMR LLC — DOUBLED
442,464 shares ($3.6M)
Price Targets
$12.44
-5.6% upside
Sell
Current $13.18
Low $10.00
Median $13.25
High $13.25
4 analysts
$10.00
$13.25
Analyst Ratings
0Strong Buy
0Buy
11Hold
1Sell
2Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 11, 2026 | Truist Securities | MAINTAIN | Hold → Hold |
| May 8, 2026 | Benchmark | DOWNGRADE | Buy → Hold |
| May 7, 2026 | Wedbush | DOWNGRADE | Outperform → Neutral |
| Mar 19, 2026 | Wedbush | UPGRADE | Neutral → Outperform |
| Mar 5, 2026 | Benchmark | UPGRADE | Hold → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.01 ▼ -36.8% | $0.00 — $0.03 | 250% YoY | 6 |
| Current FY | $0.09 ▼ -17.1% | $0.03 — $0.12 | 325% YoY | 6 |
| Next FY | $0.28 ▲ +0.5% | $0.21 — $0.35 | 231% YoY | 7 |
| Next Q | $0.04 ▼ -20.0% | $0.03 — $0.06 | 33% YoY | 6 |
Latest Reports
BULLISH
PREM14A
7/10
Cross Country Healthcare (CCRN) filed a preliminary proxy statement (PREM14A) seeking shareholder approval for its acqui
Jun 5, 2026
BULLISH
DEFA14A
8/10
Cross Country Healthcare (CCRN) entered into a definitive agreement to be acquired by Knox Lane in an all-cash transacti
May 7, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $15.4M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $7.9M | ADD |
| FMR LLC | $3.6M | DOUBLED |
| BANK OF AMERICA CORP | $2.8M | DOUBLED |
| MORGAN STANLEY | $2.1M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 31, 2026 | Hawkins Amiee | F | $5.5K |
| Mar 31, 2026 | Hawkins Amiee | A | $0.00 |
| Mar 31, 2026 | Krug Marc | A | $0.00 |
| Mar 31, 2026 | Clark Kevin | A | $0.00 |
| Mar 31, 2026 | Veizaga Marvin | F | $4.7K |
8 institutional holders with $34.0M total value (4,194,797 shares) as of 2025-Q4. Top holders: VANGUARD, CHARLES, FMR. Net buying activity: 5 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,904,150 | $15.4M | 45.4% | — |
| 2 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 969,458 | $7.9M | 23.1% | ADD +28.0% |
| 3 | FMR LLC | 442,464 | $3.6M | 10.5% | DOUBLED +1378.5% |
| 4 | BANK OF AMERICA CORP /DE/ | 343,216 | $2.8M | 8.2% | DOUBLED +430.5% |
| 5 | MORGAN STANLEY | 260,761 | $2.1M | 6.2% | ADD +72.7% |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 214,600 | $1.7M | 5.1% | TRIM -29.8% |
| 7 | WELLS FARGO & COMPANY/MN | 35,297 | $285.9K | 0.8% | ADD +43.3% |
| 8 | TWO SIGMA INVESTMENTS, LP | 24,851 | $201.3K | 0.6% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 757,533 | 969,458 | +28.0% | $7.9M | 2025-Q4 |
| FMR LLC | DOUBLED | 29,926 | 442,464 | +1378.5% | $3.6M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 64,700 | 343,216 | +430.5% | $2.8M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 24,636 | 35,297 | +43.3% | $285.9K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 24,851 | — | $201.3K | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 561,881 | 757,533 | +34.8% | $10.8M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 288,983 | 203,000 | -29.8% | $2.9M | 2025-Q3 |
| UBS Group AG | TRIM | 187,032 | 114,897 | -38.6% | $1.6M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 15,615 | 0 | -100.0% | $0.00 | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 402,230 | 561,881 | +39.7% | $7.3M | 2025-Q2 |
| MORGAN STANLEY | ADD | 188,305 | 325,144 | +72.7% | $4.2M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 175,018 | 288,983 | +65.1% | $3.8M | 2025-Q2 |
| UBS Group AG | TRIM | 306,565 | 187,032 | -39.0% | $2.4M | 2025-Q2 |
| FMR LLC | ADD | 20,530 | 36,768 | +79.1% | $479.8K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 31,751 | 15,615 | -50.8% | $203.8K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 314,877 | 402,230 | +27.7% | $6.0M | 2025-Q1 |
| UBS Group AG | DOUBLED | 130,691 | 306,565 | +134.6% | $4.6M | 2025-Q1 |
| MORGAN STANLEY | TRIM | 336,953 | 188,305 | -44.1% | $2.8M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 88,200 | 175,018 | +98.4% | $2.6M | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 45,344 | 21,372 | -52.9% | $318.2K | 2025-Q1 |
| NORGES BANK | EXIT | 111,600 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MORGAN STANLEY | TRIM | 671,714 | 336,953 | -49.8% | $6.1M | 2024-Q4 |
| UBS Group AG | TRIM | 441,801 | 130,691 | -70.4% | $2.4M | 2024-Q4 |
| NORGES BANK | NEW | — | 111,600 | — | $2.0M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 254,299 | 88,200 | -65.3% | $1.6M | 2024-Q4 |
7 unique insiders with 1 transactions. Net insider value: -$60.1K ($0.00 bought, $60.1K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | Hawkins Amiee Lin | Chief Operating Officer | F | 583 | $9.40 | $5.5K |
| Mar 31, 2026 | Hawkins Amiee Lin | Chief Operating Officer | A | 15,958 | $0.00 | $0.00 |
| Mar 31, 2026 | Krug Marc S. | Group President, Delivery | A | 21,024 | $0.00 | $0.00 |
| Mar 31, 2026 | Clark Kevin Cronin | Chief Executive Officer | A | 138,963 | $0.00 | $0.00 |
| Mar 31, 2026 | Veizaga Marvin | Chief Accounting Officer | F | 501 | $9.40 | $4.7K |
| Mar 31, 2026 | Burns William J. | Chief Financial Officer | A | 47,873 | $0.00 | $0.00 |
| Mar 31, 2026 | Veizaga Marvin | Chief Accounting Officer | A | 9,043 | $0.00 | $0.00 |
| Mar 31, 2026 | Ball Susan E | General Counsel and Secretary | A | 33,644 | $0.00 | $0.00 |
| Mar 31, 2026 | Krug Marc S. | Group President, Delivery | F | 1,123 | $9.40 | $10.6K |
| Mar 31, 2026 | Burns William J. | Chief Financial Officer | F | 2,423 | $9.40 | $22.8K |
| Mar 31, 2026 | Ball Susan E | General Counsel and Secretary | F | 1,689 | $9.40 | $15.9K |
| Mar 11, 2026 | McDonald Colin Patrick | Chief Human Resources Officer | SELL | 6,200 | $9.70 | $60.1K |
7 SEC filing reports analyzed. Sentiment: 4 bullish, 1 bearish, 1 mixed, 1 neutral. Avg impact: 6.9/10.
BULLISH
PREM14A
7/10
Cross Country Healthcare (CCRN) filed a preliminary proxy statement (PREM14A) seeking shareholder ap
Jun 5, 2026
BULLISH
DEFA14A
8/10
Cross Country Healthcare (CCRN) entered into a definitive agreement to be acquired by Knox Lane in a
May 7, 2026
BULLISH
DEFA14A
8/10
Cross Country Healthcare has entered into a definitive agreement to be acquired by private equity fi
May 7, 2026
MIXED
8-K
6/10
Cross Country Healthcare reported Q1 2026 revenue of $241.1M, down 18% YoY but above consensus of $2
May 7, 2026
BULLISH
8-K
8/10
Cross Country Healthcare (CCRN) has agreed to be acquired by Knox Lane in an all-cash transaction va
May 7, 2026
NEUTRAL
8-K
3/10
Cross Country Healthcare announced it will hold a conference call on May 7, 2026, to discuss its fir
Apr 17, 2026
BEARISH
8-K
8/10
Cross Country Healthcare reported a significant decline in financial performance for Q4 and full yea
Mar 4, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Sell (0% buy). Based on 14 analysts: 0 strong buy, 0 buy, 11 hold, 1 sell, 2 strong sell.
Analyst Price Targets
$12.44 mean target
-5.6% upside
Sell (3.00)
$10.00 Low
$13.25 High
| Metric | Value |
|---|---|
| Current Price | $13.18 |
| Target Low | $10.00 |
| Target Mean | $12.44 |
| Target Median | $13.25 |
| Target High | $13.25 |
| # Analysts | 4 |
| Recommendation | Sell (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.01 | $0.00 | $0.03 | 250.0% | -36.8% | 0↑ 1↓ | $0.2B | -11.8% | 6 |
| Current FY 2026-12-31 |
$0.09 | $0.03 | $0.12 | 325.0% | -17.1% | 1↑ 2↓ | $1.0B | -6.8% | 6 |
| Next FY 2027-12-31 |
$0.28 | $0.21 | $0.35 | 231.1% | +0.5% | 1↑ 2↓ | $1.0B | 4.2% | 7 |
| Next Q 2026-09-30 |
$0.04 | $0.03 | $0.06 | 33.3% | -20.0% | 0↑ 1↓ | $0.2B | -0.9% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.015 | |
| 7d ago | $0.021 | -0.006 |
| 30d ago | $0.024 | -0.009 |
| 60d ago | $0.016 | -0.001 |
| 90d ago | $0.017 | -0.002 |
11 analyst firms have rated this stock: 5 upgrades, 6 downgrades, 5 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 11, 2026 | Truist Securities | MAINTAIN | Hold | Hold |
| May 8, 2026 | Benchmark | DOWNGRADE | Buy | Hold |
| May 7, 2026 | Wedbush | DOWNGRADE | Outperform | Neutral |
| Mar 19, 2026 | Wedbush | UPGRADE | Neutral | Outperform |
| Mar 5, 2026 | Benchmark | UPGRADE | Hold | Buy |
| Feb 3, 2026 | Wedbush | INITIATE | — | Neutral |
| Dec 9, 2025 | UBS | MAINTAIN | Neutral | Neutral |
| Jun 17, 2025 | Barrington Research | MAINTAIN | Market Perform | Market Perform |
| May 13, 2025 | UBS | MAINTAIN | Neutral | Neutral |
| Mar 14, 2025 | Barrington Research | MAINTAIN | Market Perform | Market Perform |
| Feb 6, 2025 | JMP Securities | REITERATE | Market Perform | Market Perform |
| Dec 10, 2024 | Barrington Research | DOWNGRADE | Outperform | Market Perform |
| Dec 5, 2024 | Truist Securities | MAINTAIN | Hold | Hold |
| Nov 7, 2024 | Benchmark | MAINTAIN | Buy | Buy |
| Oct 21, 2024 | Truist Securities | MAINTAIN | Hold | Hold |
| Aug 8, 2024 | Barrington Research | MAINTAIN | Outperform | Outperform |
| Aug 1, 2024 | Truist Securities | MAINTAIN | Hold | Hold |
| May 6, 2024 | Barrington Research | MAINTAIN | Outperform | Outperform |
| May 2, 2024 | Benchmark | MAINTAIN | Buy | Buy |
| Feb 27, 2024 | Barrington Research | MAINTAIN | Outperform | Outperform |
| Feb 22, 2024 | Truist Securities | MAINTAIN | Hold | Hold |
| Feb 22, 2024 | Benchmark | MAINTAIN | Buy | Buy |
| Dec 6, 2023 | JMP Securities | INITIATE | — | Market Perform |
| Nov 30, 2023 | UBS | INITIATE | — | Neutral |
| Nov 29, 2023 | Barrington Research | MAINTAIN | Outperform | Outperform |
| Nov 3, 2023 | Truist Securities | MAINTAIN | Hold | Hold |
| Nov 3, 2023 | Jefferies | DOWNGRADE | Buy | Hold |
| Oct 5, 2023 | Jefferies | MAINTAIN | Buy | Buy |
| Aug 14, 2023 | Barrington Research | MAINTAIN | Outperform | Outperform |
| Aug 8, 2023 | Credit Suisse | MAINTAIN | Neutral | Neutral |
| Jun 26, 2023 | William Blair | INITIATE | — | Outperform |
| Jun 1, 2023 | Barrington Research | MAINTAIN | Outperform | Outperform |
| May 5, 2023 | Credit Suisse | MAINTAIN | — | Neutral |
| May 2, 2023 | Truist Securities | MAINTAIN | — | Hold |
| Mar 10, 2023 | Loop Capital | INITIATE | — | Buy |
| Feb 23, 2023 | Benchmark | MAINTAIN | — | Buy |
| Feb 23, 2023 | Credit Suisse | MAINTAIN | — | Neutral |
| Nov 7, 2022 | Barrington Research | MAINTAIN | — | Outperform |
| Oct 5, 2022 | Truist Securities | DOWNGRADE | Buy | Hold |
| Sep 15, 2022 | Benchmark | MAINTAIN | — | Buy |
| Jun 13, 2022 | Benchmark | MAINTAIN | — | Buy |
| Jun 9, 2022 | Credit Suisse | MAINTAIN | — | Neutral |
| Feb 24, 2022 | Benchmark | MAINTAIN | — | Buy |
| Jan 27, 2022 | Jefferies | UPGRADE | Hold | Buy |
| Aug 16, 2021 | Credit Suisse | MAINTAIN | — | Neutral |
| Aug 5, 2021 | Benchmark | UPGRADE | Hold | Buy |
| May 6, 2021 | Credit Suisse | MAINTAIN | — | Neutral |
| May 6, 2021 | Benchmark | DOWNGRADE | Buy | Hold |
| Feb 25, 2021 | Credit Suisse | MAINTAIN | — | Neutral |
| Nov 23, 2020 | BMO Capital | UPGRADE | Market Perform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 0 | 0 | 11 | 1 | 2 | 0% | |
| May 1, 2026 | 3 | 5 | 7 | 0 | 0 | 53% | |
| Apr 1, 2026 | 3 | 5 | 7 | 0 | 0 | 53% | |
| Mar 1, 2026 | 2 | 4 | 9 | 0 | 0 | 40% | |
| Feb 1, 2026 | 2 | 4 | 8 | 0 | 0 | 43% | |
| Jan 1, 2026 | 2 | 4 | 8 | 0 | 0 | 43% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 21, 2026
short_volume
Short Volume: CCRN — 68.6% short (0.7M / 1.1M)
Short: 733,396 | Exempt: 0 | TRF Vol: 1,069,782 | Short Ratio: 68.6% | Off-exchange volume (dark pool + OTC)
May 8, 2026
short_interest
FTD: CCRN — 374,234 shares ($4.9M) failed to deliver
Settlement: 20260508, Price: $13.09, FTD Value: $4,898,723.06, CROSS COUNTRY HEALTHCARE INC
May 7, 2026
earnings_calendar
CCRN Q1 2026 Earnings After Market Close — 2026-05-07
Mar 4, 2026
earnings_calendar
CCRN Q4 2025 Earnings After Market Close — 2026-03-04